Press Releases
Nevakar Injectables Sells Six Development-Stage, Ready-to-Use Injectable Product Candidates to Endo Ventures Limited
Nevakar announced today that it has entered into an asset sale agreement with Endo Ventures Limited, a subsidiary of Endo International plc (“Endo”) (NASDAQ: ENDP), for the sale of six of its differentiated
Read MoreNevakar Injectables Receives U.S. FDA Approval of Ready-to-Use Ephedrine Injection in a Prefilled Syringe
Nevakar Injectables Inc. announced today that the U.S. Food and Drug Administration (“FDA”) has approved its ready-to-use Ephedrine Sulfate Injection (“Ephedrine”) in a prefilled syringe (“PFS”)
Read MoreNevakar Injectables Announces the Launch of Ready-to-Use Ephedrine Injection Vials
Nevakar Injectables Inc., a biopharmaceutical company developing multiple sterile injectable products for use in the critical and ambulatory care settings, announced today the launch of its ready-to-use Ephedrine Sulfate Injection (“Ephedrine”), a formulation pre-diluted
Read MoreNevakar Announces Closing of $12 Million Convertible Note and Extension of Interest- Only Period with Oxford Finance
Nevakar Inc. (“Nevakar”), a biopharmaceutical company developing multiple assets in the ophthalmic and injectable areas, announced today that it has closed on $12 million in convertible notes with both existing and new investors.
Read MoreNEVAKAR INC. ANNOUNCES FORMATION OF NEVAKAR INJECTABLES
Nevakar Inc. (“Nevakar”), a privately held biopharmaceutical company, today announces the establishment of Nevakar Injectables Inc., a newly formed company with an established portfolio of products focused on critical patient care, acute pain management, long acting injectables
Read MoreNevakar Announces FDA Approval for Ephedrine Sulfate Injection as Ready-to-Use Vials
Nevakar Inc., a biopharmaceutical company developing multiple assets in the ophthalmic and injectable areas, announced today it received approval from the U.S. Food and Drug Administration (FDA) to market Ephedrine Sulfate Injection…
Read MoreNevakar Enters into $17.5 Million Product Financing Agreement with H.I.G. Capital Partners for Continued Development of Injectable Products
Bridgewater, NJ, OCTOBER 7, 2019 – Nevakar Inc., a specialty pharmaceutical company developing multiple assets in the ophthalmic and injectable areas, announced today that it has entered into a $17.5 million product financing agreement with an affiliate of H.I.G. Capital Partners, L.P. for the continued development of five differentiated, sterile injectable products.
Read MoreNevakar Enters $50 Million Product Financing Agreement with NovaQuest Capital for Continued Development of Injectable Products
Bridgewater, NJ, / Raleigh, NC, JUNE 18, 2019 – Nevakar Inc. (“Nevakar” or the “Company”), a specialty pharmaceutical company developing multiple assets in the ophthalmic and injectable areas, announced today that it recently entered into a $50 million product financing agreement (the “Agreement”) with an affiliate of NovaQuest Capital Management, L.L.C. for the continued development of five differentiated, sterile injectable products.
Read MoreNevakar Completes $30 Million Financing to Advance Pipeline Products
Bridgewater, NJ, NOVEMBER 29, 2018 – Nevakar Inc., a specialty pharmaceutical company developing multiple differentiated products in the ophthalmic and injectable areas, announced today that it has entered into a $20 million senior secured term loan with Oxford Finance LLC. As part of the financing agreement, Nevakar may also access an additional $10 million of funding provided that certain pre-defined milestone events are achieved. Proceeds from the financings will be used to accelerate the Company’s pipeline projects and for general corporate services.
Read More